Linked Life Data

15909946

Source:http://linkedlifedata.com/resource/pubmed/id/15909946

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:dateCreated
2005-5-24
pubmed:abstractText
Pseudoephedrine sulfate (PES) is a short-acting sympathomimetic amine and decongestant. Loratadine (L) is a long-acting antihistamine, H1 blocker. These drugs administered together provide relief from a whole range of rhinitis (hay fever) symptoms. Combination of both drugs is available in the form of sugar-coated modified-release tablets Clarinase (Schering-Plough). In this product, 5 mg of L and 60 mg of PES is present in the sugar-coating layer ready for an immediate release, and the rest of PES (60 mg) is incorporated in the extended-release core of the tablet. This enables fast as well as prolonged release of PES over 6-8 h. Because the sugar coating technologies are troublesome and rarely used nowadays, the aim of this study was to develop alternative oral dosage forms containing L (5 mg) and PES (120 mg). It was assumed that, similarly to the original product, the total dose of L and the half dose of PES should be released during 1 h and the remaining dose of PES ought to be gradually released for up to 8 h.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Dec
pubmed:issn
0001-6837
pubmed:author
pubmed:issnType
Print
pubmed:volume
61 Suppl
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
72-4
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed:year
2004
pubmed:articleTitle
Development of modified-release dosage forms containing loratadine and pseudoephedrine sulfate.
pubmed:affiliation
Department of Pharmaceutical Technology, Medical University of Gda?sk, 107 Hallera Str., 80-416 Gda?sk, Poland.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't